PatientRightsAdvocate.org Launches New York City Hospital Price Finder
New York City patients empowered to compare prices, save on care, fight surprise bills
NEW YORK, May 12, 2025 /PRNewswire/ -- Today, PatientRightsAdvocate.org (PRA) announced the New York City Hospital Price Finder Tool, empowering all who are treated in New York City hospitals with free access to all available prices so they can compare, prevent overcharges, and have recourse for surprise bills. Patients, employers, unions, and researchers in New York City are now able to search all posted prices by hospital, procedure, plan, and code at NYCHospitalPrices.org.
"The New York City Hospital Price Finder Tool is a huge step for New York City healthcare consumers, who have long suffered from hidden healthcare prices, kept secret by hospitals and insurers alike," said Cynthia Fisher, Founder and Chairman of PRA. "This tool will enable patients to easily compare actual prices, including discounted cash rates, and choose the best care at a price they can afford. Now, patients will have financial certainty as well as safeguards when their bill doesn't match the price, to protect them from overcharges."
In December 2022, New York City Council Member Julie Menin sponsored Intro. 844-A to establish the nation's first Office of Health Care Accountability to equip New Yorkers with the upfront pricing information needed for healthcare decisions. In June 2023, the legislation passed unanimously and was signed into law.
"New Yorkers will no longer live in fear that medical care will put them in financial ruin. Following our work to establish the Office of Health Care Accountability, this tool is the next step to provide New Yorkers with the resources needed to find the highest quality of care at the best price," said New York City Council Member Julie Menin. "Now, patients can easily research ahead of medical decisions with peace of mind that New York City will enforce price transparency to safeguard their physical and financial well-being."
For many patients, this tool would have made an enormous difference. The Singh family of New York City is speaking out on the value of this service.
"With upfront and real prices, we would have been able to make an informed decision on how best to proceed with our son's treatments to best help his physical health and our family's financial health. If we had been able to compare in advance, we would have been willing to drive a little further, or perhaps even had a better option nearby, to avoid the tremendous debt that has burdened our family throughout an incredibly vulnerable time," said Shameeza Singh. "We hope this tool will be a powerful resource for every patient in New York City so that devastating medical debt stories are no more and families can instead fully focus on treatment and recovery."
The first of its kind in New York City, PRA recently introduced a similar tool in Colorado and has plans to continue expanding resources for patients across the country.
"Healthcare price transparency will deliver high quality care at lower costs for patients, but that starts with easy access to prices. The New York City Hospital Price Finder will allow New Yorkers to quickly compare healthcare prices across the city," said Manny Pastreich, President of 32BJ SEIU. "We need real transparency and accountability to make informed decisions and lower costs, and this resource is a strong step in that direction."
View more photos here. View Council Member Menin's remarks here.
PatientRightsAdvocate.org (PRA) is a leading national healthcare price transparency organization dedicated to ushering in systemwide transparency through advocacy, testimony, media, legal research, and grassroots campaigns. PRA believes that the availability and visibility of actual, upfront healthcare prices will greatly lower costs for patients and employers through a functional, competitive healthcare marketplace.
View original content to download multimedia:https://www.prnewswire.com/news-releases/patientrightsadvocateorg-launches-new-york-city-hospital-price-finder-302453067.html
SOURCE Patient Rights Advocate
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All": — A subanalysis of the NefIgArd study demonstrates that early treatment can more effectively slow disease progression and reduce irreversible nephron loss. — A prospective study indicates that early treatment with NEFECON® in patients diagnosed within 6 months may better control inflammatory responses and delay disease progression. SHANGHAI, June 6, 2025 /PRNewswire/ -- At the 62nd European Renal Association Congress (ERA 2025), nine new studies on NEFECON® were presented, two of which demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy of "Treat the Cause, Treat Early, Treat All". The new results presented at ERA 2025 demonstrate early treatment with NEFECON® can help protect renal function and slow disease progression, leading to improved disease management and an improved quality of life for patients. "The new results have validated the significant role of NEFECON® in the early intervention of IgAN, and have fully demonstrated its key value in the strategy of 'Treat the Cause, Treat Early, Treat All'." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, "These findings further underscore its outstanding clinical advantages as a first-line cornerstone therapy for IgAN. The 'Treat Early' strategy offers more proactive treatment for IgAN patients, helping to control disease progression and better protect renal function. NEFECON® is the first and only fully approved etiological treatment for IgAN in China, the U.S., and Europe, providing patients with new hope and treatment options. "The new findings provide robust evidence for early targeted intervention. They show that NEFECON® significantly reduces proteinuria and protect kidney function across all diagnostic timelines, with the greatest improvements in eGFR observed in patients diagnosed within 0.6 years." Professor Ping Fu from West China Hospital of Sichuan University commented, " This demonstrates that early treatment can more effectively slow disease progression and reduce irreversible nephron loss. Additionally, early treatment with NEFECON® in patients diagnosed within 6 months may better control inflammatory responses and delay disease progression. The Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review) also recommends NEFECON® as the preferred treatment to reduce Gd-IgA1. These results emphasize the importance of early treatment for IgAN and provide valuable guidance for clinical practice." The new results provide a strong evidence-based support for NEFECON®'s variable effects depending on treatment timing and disease duration. In a subanalysis of the NefIgArd study[1], which assessed the renal benefits of budesonide delayed-release capsules (16 mg/day) across different diagnostic timelines, 364 primary IgAN patients were stratified into quartiles based on time since biopsy-confirmed diagnosis. Results showed that NEFECON® preserved eGFR and reduced UPCR versus placebo across all quartiles, with the most significant renal protection in recently diagnosed patients. For those diagnosed <0.6 years prior to baseline, NEFECON® increased eGFR by +6.41, +5.78, and +4.79 mL/min/1.73 m² at 9, 12, and 24 months, respectively, and reduced UPCR by 51.12% at 12 months. In a prospective study evaluating the impact of budesonide on inflammatory processes in recently diagnosed versus long-standing IgAN patients[2], eligible Caucasian adults were divided into two groups: recent diagnosis (RD, n=8, ≤6 months) and established diagnosis (OD, n=6, >6 months). The RD group showed a significant increase in CLU levels from 48.38 pg/ml at baseline (T0) to 94.92 pg/ml at 3 months (T3) (p=0.036), while no significant change was observed in the OD group. This suggests that early NEFECON® treatment may modulate the renal immune microenvironment, triggering protective protein expression (e.g., CLU) to repair damage. Moreover, eGFR in the RD group gradually improved from T0 to T10, indicating better renal preservation with early intervention. NEFECON®, as the only in-disease IgAN treatment has been included in the KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV) (public review draft), making it the only targeted therapy endorsed by both international and Chinese guidelines. About NEFECON® NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models. In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong, Macau, Taiwan (China) and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicines' territories. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at Forward-Looking Statements: This press release may contain forward-looking statements based on current expectations, involving risks and uncertainties. Actual results may differ materially due to various factors. The company undertakes no obligation to update these statements unless required by law. References: 1. Lafayette R, et al. Abstract#3251-Nefecon provides kidney benefit irrespective of time since diagnosis in patients with IgAN: a subanalysis of the NefIgArd study. Presented at ERA 2025. 2. Keskinis C, et al. Abstract#2093-Targeted-Release Budesonide (TRB) treatment may have different effects on the inflammatory process in IgAN patients with recent and old diagnosis. Presented at ERA 2025. View original content: SOURCE Everest Medicines Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
M-novator Demo Day Ignites Medical Innovation, Shaping the Future of MedTech
TAIPEI, June 6, 2025 /PRNewswire/ -- On the opening day of Medical Taiwan 2025, Mosaic Venture Lab, as a partner of the M-novator, is dedicated to acting as a bridge connecting Taiwan's and international innovative energy. Through its investment and ecosystem collaboration platform, it accelerates the growth of global high-quality startups in Taiwan, fosters cross-border collaborations, and brings more international funding and business opportunities to Taiwan's smart healthcare industry. The M-novator startup teams hail from Taiwan, the United States, South Korea, Belgium, and Israel. Examples include US-based InFocus Therapeutics, which focuses on developing RNA-targeted drugs, and Taiwan's own Pulxion, which has made breakthroughs in AI carotid artery detection, showcasing the international vitality of medical innovation. These pioneering startups, whose technologies represent cutting-edge advancements in the medical field, showcased in their Demo Day pitches precision artificial intelligence for diagnostics and data analysis, intuitive digital health platforms, seamless integration of medical devices (such as advanced endoscopes and smart wearables), and data-driven clinical decision support tools. A key theme of Medical Taiwan 2025 is the significant contribution of ecosystem builders in nurturing early-stage startups to achieve global impact. Johnny Yu, Founder and Chairman of CellTech Innovation Venture Studio and Managing Director of Mosaic Venture Lab, delivered a keynote speech on global MedTech trends and pressures, covering population aging, complex regulatory frameworks, and lengthy development cycles. Johnny highlighted key obstacles faced by early-stage startups: the lab-to-market translation gap, complex regulatory hurdles, funding constraints, and the complexities of market entry. He emphasized that ecosystem builders such as accelerators, venture studios, academic incubators, and government innovation departments play a crucial role in overcoming these challenges. Ryan Jin, Manager at Singapore's Centre for Healthcare Innovation, emphasized in his speech that while innovation is crucial, its effective integration into existing healthcare systems requires strategic partnerships. He acknowledged the common difficulties in collaboration between startups and healthcare institutions, citing systemic misalignments, "last-mile" barriers, and a lack of bridging infrastructure. To overcome these issues, Ryan stressed the need for streamlined processes, strong support for innovation adoption, and the establishment of clear communication channels. A highlight of the Demo Day, the panel discussion "Navigating Taiwan's MedTech Ecosystem" featured panelists including Jowy Tani, CEO of Taipei Medical University BioMed Accelerator; Nina Feng, Managing Director of Vivo Capital Taiwan; and Yenchen Huang, Vice President of Diamond Biofund. The panel aims to provide actionable insights for international MedTech and AI startups seeking to enter and thrive in the Taiwanese and Asian markets, focusing on strategies for clinical adoption, supply chain collaboration, and market entry. Mosaic Venture Lab is a venture capital accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models, and is dedicated to discovering and nurturing innovative technologies from Taiwan, Japan, and South Korea to connect with major European and American companies. Media Contact:Jade ChengSr. Project ManagerMosaic Venture Lab - Partner of Medical Taiwan 2025 M-novatorEmail: jc@ Website: View original content to download multimedia: SOURCE Mosaic Venture Lab Co.,Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
M-novator Demo Day Ignites Medical Innovation, Shaping the Future of MedTech
TAIPEI, June 6, 2025 /PRNewswire/ -- On the opening day of Medical Taiwan 2025, Mosaic Venture Lab, as a partner of the M-novator, is dedicated to acting as a bridge connecting Taiwan's and international innovative energy. Through its investment and ecosystem collaboration platform, it accelerates the growth of global high-quality startups in Taiwan, fosters cross-border collaborations, and brings more international funding and business opportunities to Taiwan's smart healthcare industry. The M-novator startup teams hail from Taiwan, the United States, South Korea, Belgium, and Israel. Examples include US-based InFocus Therapeutics, which focuses on developing RNA-targeted drugs, and Taiwan's own Pulxion, which has made breakthroughs in AI carotid artery detection, showcasing the international vitality of medical innovation. These pioneering startups, whose technologies represent cutting-edge advancements in the medical field, showcased in their Demo Day pitches precision artificial intelligence for diagnostics and data analysis, intuitive digital health platforms, seamless integration of medical devices (such as advanced endoscopes and smart wearables), and data-driven clinical decision support tools. A key theme of Medical Taiwan 2025 is the significant contribution of ecosystem builders in nurturing early-stage startups to achieve global impact. Johnny Yu, Founder and Chairman of CellTech Innovation Venture Studio and Managing Director of Mosaic Venture Lab, delivered a keynote speech on global MedTech trends and pressures, covering population aging, complex regulatory frameworks, and lengthy development cycles. Johnny highlighted key obstacles faced by early-stage startups: the lab-to-market translation gap, complex regulatory hurdles, funding constraints, and the complexities of market entry. He emphasized that ecosystem builders such as accelerators, venture studios, academic incubators, and government innovation departments play a crucial role in overcoming these challenges. Ryan Jin, Manager at Singapore's Centre for Healthcare Innovation, emphasized in his speech that while innovation is crucial, its effective integration into existing healthcare systems requires strategic partnerships. He acknowledged the common difficulties in collaboration between startups and healthcare institutions, citing systemic misalignments, "last-mile" barriers, and a lack of bridging infrastructure. To overcome these issues, Ryan stressed the need for streamlined processes, strong support for innovation adoption, and the establishment of clear communication channels. A highlight of the Demo Day, the panel discussion "Navigating Taiwan's MedTech Ecosystem" featured panelists including Jowy Tani, CEO of Taipei Medical University BioMed Accelerator; Nina Feng, Managing Director of Vivo Capital Taiwan; and Yenchen Huang, Vice President of Diamond Biofund. The panel aims to provide actionable insights for international MedTech and AI startups seeking to enter and thrive in the Taiwanese and Asian markets, focusing on strategies for clinical adoption, supply chain collaboration, and market entry. Mosaic Venture Lab is a venture capital accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models, and is dedicated to discovering and nurturing innovative technologies from Taiwan, Japan, and South Korea to connect with major European and American companies. Media Contact:Jade ChengSr. Project ManagerMosaic Venture Lab - Partner of Medical Taiwan 2025 M-novatorEmail: jc@ Website: View original content to download multimedia: SOURCE Mosaic Venture Lab Co.,Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
